Ligand profile

KET

Ligand co-crystallized with a similar protein (Protein Data Bank).

Bound to: VK055_3030 — tyrosine aminotransferase

Via homolog PDB 4rkd UniProt C7E5X4 Formula C₁₂H₁₆N₂O₉P⁺
Mol. weight 363.24 Da
Permeability Check
PAINS Clean

Identifiers

Database identifiers and provenance.

Ligand ID
KET
PDB
4rkd
UniProt (similar protein)
C7E5X4
Target protein
VK055_3030

Structure

2D representation rendered from SMILES.

Physicochemical properties

Computed with RDKit from SMILES.

Molecular weight 363.24 Da
LogP (Crippen) -0.53
H-bond donors 5
H-bond acceptors 6
TPSA 188.09 Ų
Rotatable bonds 8
Aromatic rings 1 / 1
Heavy atoms 24
Fraction sp³ C 0.33
Formula C₁₂H₁₆N₂O₉P⁺

Drug-likeness

Descriptor-based ADME screening flags from SMILES. These are not experimental toxicity results.

Permeability proxy Check

Estimated from TPSA and LogP only: TPSA ≤ 90 Ų and −1 ≤ LogP ≤ 5 are treated as a favorable small-molecule permeability screen.

  • TPSA ≤ 90 Ų 188.1
  • −1 ≤ LogP ≤ 5 -0.53
Lipinski's Rule of Five Pass 0 violations
  • MW ≤ 500 Da 363.2
  • LogP ≤ 5 -0.53
  • H-bond donors ≤ 5 5
  • H-bond acceptors ≤ 10 6
Veber's rules Fail
  • Rotatable bonds ≤ 10 8
  • TPSA ≤ 140 Ų 188.1
PAINS Clean

No PAINS structural alerts detected.

Chemical representations

Canonical representations for cheminformatics workflows.

SMILES 
Cc1c(c(c(c[nH+]1)COP(=O)(O)O)C=NC(CC(=O)O)C(=O)O)O
InChI 
InChI=1S/C12H15N2O9P/c1-6-11(17)8(4-14-9(12(18)19)2-10(15)16)7(3-13-6)5-23-24(20,21)22/h3-4,9,17H,2,5H2,1H3,(H,15,16)(H,18,19)(H2,20,21,22)/p+1
InChIKey 
OEULMZWKJBFRJF-UHFFFAOYSA-O

Provenance

Annotation context from LigQ_2, the internal Target step that collects PDB, ChEMBL, and ZINC ligand evidence.

Method
LigQ nearest_k
Source
PDB
Binding sites
PF00155

External resources

Open this ligand in third-party databases and cheminformatics tools.

Other ligands for this protein

Quick navigation to other ligands bound to VK055_3030.

PDB 30

Ligands co-crystallized with this protein (structural evidence).

Ligand PDB entry

ZINC 50

Virtual screening candidates selected by structural similarity to known actives (Tanimoto ≥ 0.5).

Compound Similarity (Tanimoto)